Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

Bullboard (NDAQ:PMN)

View:
Comment by Gbathaton Jun 15, 2024 2:00am

RE:RE:Unanimous 11-0

Yikes, 31% ARIA-E for donanemab  How PMN is still not financed through Ph2 or bought out at this point is beyond me. 
Post by Jonathon Brownon Jun 13, 2024 8:36am

Buzz on the Bullboards: TSX spotlight – Bombardier, Sonoro, PyroGenesis

Post by goldtechon Jun 12, 2024 10:23pm

Precision Medicine / AI

https://www.fiercebiotech.com/biotech/foresite-raises-900m-make-big-bets-one-best-biotech-investment-environments
Comment by goldtechon Jun 12, 2024 7:43pm

RE:RE:RE:Bad news for you.

Scientists all agree soluble toxic oligomers kill neurons, so targeting only the oligomers should stop the propagation of the very toxic proteins that the medical community agrees is the root cause.
Comment by Alex1726on Jun 12, 2024 6:43pm

RE:RE:Bad news for you.

Well ok but what does it change to the fact that eleminating the bad proteins is not the right target?
Post by goldtechon Jun 12, 2024 5:21pm

Promis has it correct

We’re advocating that what may be more meaningful across all degenerative diseases is the loss of normal proteins rather than the measurable fraction of abnormal proteins,” Espay said. “The net effect ...more  
Comment by G1945Von Jun 12, 2024 10:15am

RE:Bad news for you.

He did not explain how the soluble (amyloid beta) normal protein gets generated in the brain to maintain brain function and keep neurons communicating with one another. G1945V
Post by Alex1726on Jun 12, 2024 8:14am

Bad news for you.

PMN and most of others working to eleminate misfolded proteins got it all wrong. https://www.uc.edu/news/articles/2022/09/decreased-proteins-not-amyloid-plaques-tied-to-alzheimers.html
Comment by G1945Von Jun 12, 2024 6:06am

RE:Unanimous 11-0

"The main safety concerns of donanemab are brain swelling (edema) and micro-bleeding (hemorrhages), both known as amyloid-related imaging abnormalities, or ARIA. In the clinical trial, among ...more  
Post by G1945Von Jun 12, 2024 5:41am

Business Insider:Buy Rating Affirmed for ProMIS Neuroscience

https://markets.businessinsider.com/news/stocks/buy-rating-affirmed-for-promis-neurosciences-amid-positive-fda-feedback-and-promising-alzheimer-s-treatment-outlook-1033467319 "with lower risks ...more  
Post by Trek1701on Jun 11, 2024 8:41pm

Unanimous 11-0

https://www.forbes.com/sites/joshuacohen/2024/06/11/alzheimers-disease-drug-donanemab-gets-unanimous-backing-from-fda-expert-panel/ 1736 patients enrolled in p3. 25% ARIA. 5% underrepresented ...more  
Comment by M101on Jun 10, 2024 5:33pm

RE:Predictions for June?

I predict donanemab gets unanimous backing from FDA advisory committee earlier today. Because money has spoken. Hurray for money, wish we had some.    
Post by Gbathaton Jun 07, 2024 7:18pm

Predictions for June?

Phase 1a results announced? Phase 1b financing? Phase 2a financing?
Post by Alex1726on Jun 06, 2024 4:23pm

Getting more and more difficult for Mab

https://www.biopharmadive.com/news/lilly-donanemab-alzheimers-fda-advisory-committee-documents/718194/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue
Post by goldtechon Jun 05, 2024 10:24am

Poor management

This Company has always had management problems and their burn rate is pathetic for a biotech that gives out money like it's never ending. This lame BOD does nothing but drain the treasury.
Comment by G1945Von Jun 05, 2024 10:01am

RE:How low will it go 2.0?

We saw 97 cents on Dec 26, 2023. G1945V
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities